scholarly journals Percutaneous Aortic Valve-in-Valve Implantation: Transcatheter Intervention for Failing Bioprosthetic Valves in High-Risk Patients

2017 ◽  
Vol 26 ◽  
pp. S223
Author(s):  
N. Bart ◽  
S. Hungerford ◽  
R. Spina ◽  
D. Muller ◽  
D. Roy
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Transcatheter Intervention ◽  
High Risk Patients ◽  
Risk Patients ◽  
Valve In Valve ◽  
Valve Implantation ◽  
Bioprosthetic Valves

Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients

2012 ◽  
Vol 366 (18) ◽  
pp. 1705-1715 ◽  
Author(s):  
Martine Gilard ◽  
Hélène Eltchaninoff ◽  
Bernard Iung ◽  
Patrick Donzeau-Gouge ◽  
Karine Chevreul ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Analysis of Survival in 300 High-Risk Patients up to 2.5 Years After Transapical Aortic Valve Implantation

2011 ◽  
Vol 92 (4) ◽  
pp. 1315-1323 ◽  
Author(s):  
Axel Unbehaun ◽  
Miralem Pasic ◽  
Thorsten Drews ◽  
Stephan Dreysse ◽  
Marian Kukucka ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
High Risk Patients ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Sutureless Aortic Valve Implantation through an Upper V-Type Ministernotomy: An Innovative Approach in High-Risk Patients

2013 ◽  
Vol 8 (1) ◽  
pp. 23-28 ◽  
Author(s):  
Giovanni Concistrè ◽  
Antonio Miceli ◽  
Francesca Chiaramonti ◽  
Pierandrea Farneti ◽  
Stefano Bevilacqua ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Minimally Invasive ◽  
Minimally Invasive Approach ◽  
Invasive Approach ◽  
High Risk Patients ◽  
Risk Patients ◽  
The Mean ◽  
Valve Implantation

Objective Aortic valve replacement in minimally invasive approach has shown to improve clinical outcomes even with a prolonged cardiopulmonary bypass and aortic cross-clamp (ACC) time. Sutureless aortic valve implantation may ideally shorten operative time. We describe our initial experience with the sutureless 3f Enable (Medtronic, Inc, ATS Medical, Minneapolis, MN USA) aortic bioprosthesis implanted in minimally invasive approach in high-risk patients. Methods Between May 2010 and May 2011, thirteen patients with severe aortic stenosis underwent aortic valve replacement with the 3f Enable bioprosthesis through an upper V-type ministernotomy interrupted at the second intercostal space. The mean ± SD age was 77 ± 3.9 years (range, 72–83 years), 10 patients were women, and the mean ± SD logistic EuroSCORE was 15% ± 13.5%. Echocardiography was performed preoperatively, at postoperative day 1, at discharge, and at follow-up. Clinical data, adverse events, and patient outcomes were recorded retrospectively. The median follow-up time was 4 months (interquartile range, 2–10 months). Results Most of the implanted valves were 21 mm in diameter (19–25 mm). The CPB and ACC times were 100.2 ± 25.3 and 66.4 ± 18.6 minutes. At short-term follow-up, the mean ± SD pressure gradient was 14 ± 4.9 mm Hg; one patient showed trivial paravalvular leakage. No patients died during hospital stay or at follow-up. Conclusions The 3f Enable sutureless bioprosthesis implanted in minimally invasive approach through an upper V-type ministernotomy is a feasible, safe, and reproducible procedure. Hemodynamic and clinical data are promising. This innovative approach might be considered as an alternative in high-risk patients. Reduction of CPB and ACC time is possible with increasing of experience and sutureless evolution of actual technology.

Sign in / Sign up

Export Citation Format

Share Document